In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 58.7% compared to the same period last year. Revenues are forecasted to be $379.96 million, representing a year-over-year decrease of 11.6%.The consensus EPS estimate for the quarter has been revised 152.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

The upcoming report from Lineage, Inc. (LINE) is expected to reveal quarterly earnings of $0.73 per share, indicating a decline of 12.1% compared to the year-ago period. Analysts forecast revenues of $1.37 billion, representing an increase of 2.3% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, i ...

The upcoming report from Viatris (VTRS) is expected to reveal quarterly earnings of $0.52 per share, indicating a decline of 3.7% compared to the year-ago period. Analysts forecast revenues of $3.52 billion, representing a decline of 0.3% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ear ...

Core Insights - APA is expected to report quarterly earnings of $0.62 per share, a decline of 21.5% year-over-year, with revenues forecasted at $1.92 billion, reflecting a decrease of 23.2% compared to the same period last year [1] Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 5.1%, indicating a collective reassessment by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are strongly correlated with short-term stock price performance [3] Revenue Projections - Analysts estimate 'Oil, natural gas, and natural gas liquids production revenues - Natural gas revenues' at $173.84 million, a year-over-year increase of 2.3% [5] - The estimate for 'Oil, natural gas, and natural gas liquids production revenues' is projected at $1.58 billion, indicating a decline of 27.7% from the prior year [5] - 'Oil, natural gas, and natural gas liquids production revenues - Natural gas liquids revenues' are expected to reach $130.99 million, down 30.7% year-over-year [6] - 'Oil, natural gas, and natural gas liquids production revenues - Oil revenues' are forecasted at $1.30 billion, reflecting a decrease of 29.2% from the previous year [6] Regional Revenue Estimates - 'Revenues - United States' are projected to be $962.01 million, a significant decline of 43.6% year-over-year [7] - 'Revenues - North Sea' are estimated at $151.33 million, indicating a drop of 50.6% from the prior year [7] - 'Revenues - Egypt' are expected to be $617.34 million, down 11.7% compared to the previous year [7] Production Volume Estimates - Total production volume per day is expected to reach 437 thousand barrels of oil equivalent, down from 488 thousand barrels a year ago [8] - 'Production volume per day - NGL - Total' is projected at 67.61 thousand barrels, compared to 81.70 thousand barrels in the same quarter last year [9] - 'Production volume per day - Oil - Total' is expected to be 230.65 thousand barrels, down from 265.18 thousand barrels in the same quarter last year [10] Stock Performance - Over the past month, APA shares have returned +13.8%, while the Zacks S&P 500 composite has seen a -0.8% change [11] - APA currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [11]

Core Insights - Wall Street analysts expect Zoom Communications (ZM) to report quarterly earnings of $1.48 per share, reflecting a year-over-year increase of 5% [1] - Revenue is anticipated to reach $1.23 billion, which is a 4.1% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating a reassessment of projections by analysts [1] Revenue Estimates - Geographic Revenue from Asia Pacific (APAC) is expected to be $150.92 million, showing a 3% increase from the prior year [4] - Geographic Revenue from Europe, Middle East, and Africa (EMEA) is projected to reach $195.15 million, indicating a 4.3% increase year-over-year [4] - Geographic Revenue from the Americas is forecasted at $886.69 million, reflecting a 4.2% increase from the previous year [4] Customer Metrics - The average prediction for Enterprise Customers stands at 187,139, down from 192,600 in the same quarter last year [5] - Analysts estimate that Customers generating over $100K in TTM Revenue will total 4,431, compared to 4,088 in the same quarter last year [5] Performance Obligations - Current Remaining Performance Obligation (RPO) is expected to be $2.40 billion, up from $2.25 billion reported in the same quarter last year [6] - Remaining Performance Obligations (RPO) are estimated at $4.05 billion, compared to $3.80 billion in the same quarter last year [6] - Non-Current Remaining Performance Obligation (RPO) is projected to reach $1.64 billion, an increase from $1.55 billion reported in the same quarter last year [7] Stock Performance - Over the past month, Zoom shares have returned +7.5%, while the Zacks S&P 500 composite has seen a -0.8% change [7] - Currently, ZM holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7]

Core Insights - Permian Resources (PR) is expected to report quarterly earnings of $0.28 per share, a decline of 22.2% year-over-year, with revenues forecasted at $1.28 billion, reflecting a decrease of 0.9% compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised 12.4% lower in the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Production Metrics - Analysts predict 'Average daily net production - Total' to reach 403,909 barrels of oil equivalent per day, up from 368,414 barrels per day a year ago [5] - 'Average daily net production - Natural gas' is estimated at 679,771 thousand cubic feet per day, compared to 634,546 thousand cubic feet per day last year [5] - 'Average daily net production - NGL' is projected at 102,533 barrels per day, an increase from 91,382 barrels per day a year ago [6] - 'Average daily net production - Oil' is expected to be 188,760 barrels per day, up from 171,274 barrels per day in the same quarter last year [6] Sales Price Estimates - The estimated 'Average sales prices - Oil - Including Derivative Cash Settlements' is $62.18, down from $70.75 a year ago [7] - 'Average sales prices - NGL - Excluding the effects of GP&T' is forecasted to be $15.71, compared to $24.05 in the same quarter last year [7] - The average prediction for 'Average sales prices - Oil - Excluding the effects of hedging' is $58.60, down from $69.66 a year ago [8] Stock Performance - Over the past month, shares of Permian Resources have returned +22.4%, while the Zacks S&P 500 composite has changed by -0.8% [8] - Currently, PR holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]

Core Viewpoint - TKO Group Holdings is expected to report a significant decline in quarterly earnings per share, while revenues are projected to increase substantially year-over-year [1]. Earnings Estimates - Analysts predict TKO Group will post quarterly earnings of $0.14 per share, reflecting a 60% decline compared to the same period last year [1]. - Over the last 30 days, the consensus EPS estimate has been revised downward by 3.5%, indicating a reassessment by analysts [2]. Revenue Projections - Total revenues are forecasted to be $1.02 billion, representing a year-over-year increase of 59.5% [1]. - Specific revenue estimates include: - 'Net Revenue- UFC- Consumer products licensing and other' at $14.31 million, a change of +0.8% year-over-year [5]. - 'Net Revenue- WWE' estimated at $346.68 million, indicating a +16.2% change [5]. - 'Net Revenue- UFC' projected to reach $382.79 million, reflecting an +11.3% change [5]. - 'Net Revenue- UFC- Media rights, production and content' at $223.56 million, a +12.9% change [6]. - 'Net Revenue- UFC- Live events and hospitality' expected to be $72.78 million, a +12.7% change [6]. - 'Net Revenue- UFC- Partnerships and marketing' estimated at $72.15 million, a +7.5% change [7]. - 'Net Revenue- WWE- Media rights, production and content' projected at $226.25 million, indicating a +44.8% change [7]. Event Metrics - Analysts estimate 'UFC - Numbered events' to remain at 4, consistent with the previous year [8]. - 'UFC - Fight Nights' is expected to reach 7, up from 6 in the same quarter last year [8]. - Total 'UFC - Total events' is projected at 11, compared to 10 in the same quarter of the previous year [8]. - For event locations, 'UFC - Location of events - International' is expected to increase to 4 from 3 last year, while 'UFC - Location of events - United States' remains at 7 [9]. Stock Performance - TKO Group shares have increased by 4.3% over the past month, contrasting with a -0.8% change in the Zacks S&P 500 composite [9].

Core Viewpoint - Analysts forecast that United Therapeutics (UTHR) will report quarterly earnings of $6.78 per share, reflecting a year-over-year increase of 9.5%, with anticipated revenues of $805.31 million, marking a 9.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Adcirca' will reach $4.62 million, a decrease of 1.6% from the year-ago quarter [5]. - The average prediction for 'Revenues- Orenitram' is $121.24 million, indicating a year-over-year increase of 12.5% [5]. - The consensus for 'Revenues- Other products' stands at $5.10 million, reflecting a year-over-year decline of 7.3% [5]. - 'Revenues- Remodulin' is expected to be $131.46 million, showing a decrease of 2.3% year over year [6]. - 'Revenues- Tyvaso' is projected to reach $488.25 million, indicating a year-over-year increase of 17.4% [6]. - 'Revenues- Unituxin' is expected to be $51.29 million, suggesting a significant decline of 24% year over year [6]. - 'Revenues- Nebulized Tyvaso' is forecasted at $144.35 million, reflecting a slight increase of 1.2% from the prior year [7]. - 'Revenues- Tyvaso DPI' is expected to reach $313.30 million, indicating a year-over-year increase of 14.7% [7]. - 'Revenues- United States' is projected to be $753.92 million, reflecting a change of 6.8% from the prior-year quarter [7]. - 'Revenues- Rest-of-World' is estimated at $28.71 million, suggesting a year-over-year decline of 4.9% [8]. Stock Performance - Over the past month, shares of United Therapeutics have returned +1.8%, contrasting with the Zacks S&P 500 composite's -0.8% change [8]. - Currently, UTHR holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].

Core Viewpoint - The market anticipates Mirum Pharmaceuticals, Inc. (MIRM) to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Earnings Expectations - The consensus EPS estimate for Mirum Pharmaceuticals is $0.02 per share, reflecting a year-over-year increase of +104.1% [3] - Expected revenues are projected to be $141.27 million, which is an increase of 42.1% compared to the same quarter last year [3] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 50.88% higher, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Mirum Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +675.00% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Mirum Pharmaceuticals currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Mirum Pharmaceuticals was expected to post a loss of $0.1 per share but instead reported earnings of $0.05, resulting in a surprise of +150.00% [13] - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14] Industry Context - Another company in the same industry, Tarsus Pharmaceuticals, Inc. (TARS), is expected to report a loss of $0.19 per share, with revenues projected at $144.96 million, reflecting a year-over-year increase of 118.3% [18][19] - Tarsus Pharmaceuticals has an Earnings ESP of +136.84% and a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [20]

Core Viewpoint - Dolby Laboratories (DLB) has shown a recent stock price increase of 3.3% over the past four weeks, with a mean price target of $89.25 indicating a potential upside of 40.2% from the current price of $63.65 [1] Price Targets and Estimates - The mean estimate for DLB comprises four short-term price targets with a standard deviation of $19, where the lowest estimate is $68.00 (6.8% increase) and the highest is $114.00 (79.1% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about DLB's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 6.8% increase over the past month with two upward revisions and no negative revisions [11][12] - DLB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]